Galera shares take a nosedive in the wake of unexpected PhIII flop
Galera was sure it had a winner when it launched its pivotal severe oral mucositis (SOM) trial back in 2018 — and so were investors. Fresh …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
